Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)
Shots:
- Pfizer to get exclusive rights for development and commercialization of AnTolRx's lead immunotherapeutic for T1D. AnTolRx to receive upfront- milestones & royalties on sales
- Under the June 2016 agreement- Pfizer exercised its option to license AnTolRx’s T1D candidate
- AnTolRx develops antigen-specific therapies- based on immune tolerance induction- for inflammatory and autoimmune diseases including T1D- RA- IBD- and Celiac disease
Ref: AnTolRx | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
